KRAS mutations and NRAS Q61 predict worse outcomes in MM. (A) Survival curves comparing the clinical outcome of newly-diagnosed MM patients with and without activating RAS mutations (CoMMpass release IA11). (B) KRAS-mutated MM patients vs all other patients. (C) Activating KRAS vs NRAS mutations. (D) Codon-61 NRAS mutations vs other NRAS variants. All analyses were performed at VAF cutoffs of 0 and 0.3 to assess the effect of tumor heterogeneity on survivorship, with 0.3 as a signifier of a largely dominant RAS-mutated clone for this heterozygous mutation. P values from log-rank test and the sample size for each group are reported.